@article {1532,
	title = {Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease.},
	journal = {Journal of acquired immune deficiency syndromes (1999)},
	volume = {39},
	year = {2005},
	month = {2005 May 1},
	pages = {69-77},
	abstract = {Enfuvirtide (ENF) has been shown to improve short-term virologic responses when given to highly treatment-experienced patients with advanced HIV disease. Because of the high cost of ENF compared with other antiretroviral agents, our objectives were to determine the potential long-term clinical impact and cost-effectiveness of ENF in these patients.},
	keywords = {Adult, CD4 Lymphocyte Count, Cost-Benefit Analysis, Drug Therapy, Combination, Female, HIV Envelope Protein gp41, HIV Fusion Inhibitors, HIV Infections, Humans, Male, Middle Aged, Peptide Fragments, Quality of Life, Reproducibility of Results, Sensitivity and Specificity, Survival Analysis, United States},
	issn = {1525-4135},
	doi = {10.1111/j.1524-4733.2010.00763.x},
	author = {Sax, Paul E and Losina, Elena and Weinstein, Milton C and Paltiel, A David and Goldie, Sue J and Muccio, Tammy M and Kimmel, April D and Zhang, Hong and Freedberg, Kenneth A and Walensky, Rochelle P}
}
